|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma显示文摘AIM: To assess the safety and efficacy of trans-arterial chemo-embolization (TACE) in very elderly patients. METHODS: A prospective cohort study, from 2001 to 2010, compared clinical outcomes following TACE between patients ≥ 75 years old and younger patients (aged between 65 and 75 years and younger than 65 years) with hepatocellular carcinoma (HCC), diagnosed according to the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases criteria. The decision that patients were not candidates for curative therapy was made by a multidisciplinary HCC team. Data collected included demographics, co-morbidities, liver disease etiology, liver disease severity and the number of procedures. The primary outcome was mortality; secondary outcomes included post-embolization syndrome (nausea, fever, abdominal right upper quadrant pain, increase in liver enzymes with no evidence of sepsis and with a clinical course limited to 3-4 d post procedure) and 30-d complications. Additionally, changes in liver enzyme measurements were assessed [alanine and aspartate aminotransferase (ALT and AST), gamma-glutamyl transpeptidase and alkaline phosphatase] in the week following TACE. Analysis employed both univariate and multivariate methods (Cox regression models). RESULTS: Of 102 patients who underwent TACE as sole treatment, 10 patients (9.8%) were > 80 years old at diagnosis; 13 (12.7%) were between 75 and 80 years, 45 (44.1%) were between 65 and 75 years and 34 (33.3%) were younger than 65 years. Survival analysis demonstrated similar survival patterns between the elderly patients and younger patients. Age was also not associated with the adverse event rate. Survival rates at 1, 2 and 3 years from diagnosis were 74%, 37% and 31% among patients < 65 years; 83%, 66% and 48% among patients aged 65 to 75 years; and 86%, 41% and 23% among patients ≥ 75 years. There were no differences between the age groups in the pre-procedural care, including preventive treatment for contrast nephropathy and prophylactic antibiotics. Multivariate survival analysis, controlling for disease stage at diagnosis with the Barcelona Clinic Liver Cancer score, number of TACE procedures, sex and alphafetoprotein level at the time of diagnosis, found no significant difference in the mortality hazard for elderly vs younger patients, and there were no differences in post-procedural complications. Serum creatinine levels did not change after 55% of the procedures, in all age groups. In 42% of all procedures, serum creatinine levels increased by no more than 25% above the baseline levels prior to TACE. Overall, there were 69 post-embolization events (23%). Hepatocellular enzymes often increased following TACE, with no association with prognosis. In 40% of the procedures, ALT and AST levels rose by at least 100%. The increases in hepatocellular enzymes occurred similarly in all age groups. CONCLUSION: TACE is safe and effective in very elderly patients with HCC, and is not associated with decreased survival or increased complication rates. | Matan J Cohen Allan I Bloom Orly Barak Alexander Klimov Tova Nesher Daniel Shouval Izhar Levi Oren Shibolet | 2013 | World Journal of Gastroenterology2013，19，16： | 13 |
| 2 | Fever of unknown origin:a retrospective review of pediatric patients from an urban,tertiary care center in Washington,DC显示文摘Background Fever of unknown origin(FUO)continues to challenge clinicians to determine an etiology and the need for treatment.This study explored the most common etiologies,characteristics,and average cost of hospitalization for FUO in a pediatric population at an urban,tertiary care hospital in Washington,DC.Methods Records from patients admitted to Children's National Health System between September 2008 and April 2014 with an admission ICD-9 code for fever(780.6)were reviewed.The charts of patients 2-18 years of age with no underlying diagnosis and a temperature greater than 38.3℃for 7 days or more at time of hospitalization were included.Final diagnoses,features of admission,and total hospital charges were abstracted.Results 110 patients qualified for this study.The majority of patients(n=42,38.2%)were discharged without a diagnosis.This was followed closely by infection,accounting for 37.2%(n=41)of patients.Rheumatologic disease was next(n=16,14.5%),followed by miscellaneous(n=6,5.4%)and oncologic diagnoses(n=5,4.5%).The average cost of hospitalization was 40,295 US dollars.Conclusions This study aligns with some of the most recent publications which report undiagnosed cases as the most common outcome in patients hospitalized with FUO.Understanding that,often no diagnosis is found may reassure patients,families,and clinicians.The cost associated with hospitalization for FUO may cause clinicians to reconsider inpatient admission for diagnostic work-up of fever,particularly given the evidence demonstrating that many patients are discharged without a diagnosis. | Ann Marie Szymanski Hugo Clifford Tova Ronis | 2020 | World Journal of Pediatrics2020，16，2： | 2 |
| 3 | Rabbit model for in vivo study of anthracycline induced heart failure and for the evaluation of protective agents显示文摘 | Simunek T Klim tova I Kap lanova J etal | 2004 | Eur J Heart Fail2004，6，4： | 1 |
| 4 | A micro flow injection electrochemical biosensor for organophosphorus pesticides 显示文摘 | TOVA N INNA E EREZ C | 2000 | Biosensors & Bioelectronics2000，，15： | 1 |
| 5 | Anthracycline induced cardio toxicity显示文摘 | H rdina R Gersl V Klim tova I | 2000 | Acta Medica (HradecKralove)2000，43，3： | 1 |
| 6 | Propagation of flat-topped multi-Gaussian laser beams 显示文摘 | | 2001 | J O S A2001，18，： | 1 |
| 7 | For heaven' 5sake follow the rules: pedestrians behavior in an ultra-orthodox and a non-orthodox city显示文摘 | Tova Rosenbloom Dan Nemrodov Hadar Barkan | 2004 | Trans- portation Research part F2004，，7： | 1 |
| 8 | Molecular properties and involvement of heparanase in cancer progression and mammary gland morphagenesis显示文摘 | Eyal Z Shula M Tova CS | 2001 | J Mammary Gland Biol Neoplasia2001，6，3： | 1 |
| 9 | The needs of parents of children of cochlea implants显示文摘 | Tova M Zaidman-Zait A | 2001 | The Volta Review2001，103，： | 1 |
| 10 | Enhanced Oxidative Stress and Leucocyte Activation in Neoplastic Tissues of the Colon显示文摘 | Tova Rainis Irit Maor Amos Lanir Sergay Shnizer Alexandra Lavy | 2007 | Digestive Diseases and Sciences2007，，2： | 1 |
| 11 | Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptorredirected Human Lymphocytes显示文摘 | Tova Waks Keren Kaufman-Francis | 2003 | Cancer Research2003，63，： | 1 |
| 12 | Fear and danger appraisals of aroadcrossing scenario: A developmental perspective显示文摘 | TOVA R DAN N ADAR BE | 2008 | Accid AnalyPrevent2008，40，4： | 1 |
| 13 | A micro flow injection electrochemical biosensor for organophosphorus pesticides显示文摘 | Tova Neufeld lnna Eshkenazi Erez Cohen | 2000 | Biosens Bioelectron2000，15，526： | 1 |
| 14 | Friction Stir Welding: An innovation seam technology 显示文摘 | Tova R Gambaro C Volpone M | 2003 | Welding International2003，17，： | 1 |
| 15 | The effect of Nd: YAG laser posterior capsulotomy on ocular wave front aber- rations显示文摘 | Jaime Levy Tova Lifshitz Itamar Klemperer | 2009 | Can J Ophthalmol2009，44，： | 1 |
| 16 | Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration显示文摘 | Jaime Levy Marina Shneck Shirley Rosen Itamar Klemperer David Rand Orly Weinstein Anry Pitchkhadze Nadav Belfair Tova Lifshitz | 2009 | International Ophthalmology2009，，5： | 1 |
| 17 | Lipoprotein lipase expression exclusively in liver显示文摘 | Martin M Peter H W Tova C S | 1998 | J Clin Invest1998，102，5： | 1 |
| 18 | Friction stir welding:an innovative seam technology显示文摘 | Tova R Gambaro C Volpone M | 2003 | Welding International2003，17，： | 1 |
| 19 | Risk perception of driving as a function of advanced training aimed at recognizing and handling risks in demanding driving situations 显示文摘 | Tova R Amit S Avi E | 2008 | Nuclear Instruments and Methods in Physics Research2008，40，2： | 1 |
| 20 | A micro flow injection electrochemical biosensor for organophosphorus pesticides 显示文摘 | Tova Neufeld Inna Eshkenazi Erez Cohen | 2000 | Biosens Bioelectron2000，15，56： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员